Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00556452 · FLOW

Participant flow

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen · Source last updated 2017-12-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Clofarabine/Busulfan x 4 : Clofarabine IV 20 mg/m\^2/day x 5 days Busulfan IV 3.2 mg/kg daily x 4 days Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.
    id
    FG000
    title
    Clo/BU4 20mg/m^2
  2. description
    Clofarabine/Busulfan x 4 : Clofarabine IV 30 mg/m\^2/day x 5 days Busulfan IV 3.2 mg/kg daily x 4 days Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.
    id
    FG001
    title
    Clo/BU4 30mg/m^2
  3. description
    Clofarabine/Busulfan x 4 : Clofarabine IV 40 mg/m\^2/day x 5 days Busulfan IV 3.2 mg/kg daily x 4 days Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.
    id
    FG002
    title
    Clo/BU4 40mg/m^2
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        21
      3. group Id
        FG002
        num Subjects
        19
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        21
      3. group Id
        FG002
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients with relapsed or refractory hematologic malignancies not in remission received unmanipulated HSCT with CloBu4 conditioning from October 2007 to November 2009 at the University of Michigan. Patients received a clofarabine dose of 20mg/m\^2, 30 mg/m\^2 or 40 mg/m\^2.
Complete source fields
groups
  1. description
    Clofarabine/Busulfan x 4 : Clofarabine IV 20 mg/m\^2/day x 5 days Busulfan IV 3.2 mg/kg daily x 4 days Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.
    id
    FG000
    title
    Clo/BU4 20mg/m^2
  2. description
    Clofarabine/Busulfan x 4 : Clofarabine IV 30 mg/m\^2/day x 5 days Busulfan IV 3.2 mg/kg daily x 4 days Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.
    id
    FG001
    title
    Clo/BU4 30mg/m^2
  3. description
    Clofarabine/Busulfan x 4 : Clofarabine IV 40 mg/m\^2/day x 5 days Busulfan IV 3.2 mg/kg daily x 4 days Peripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.
    id
    FG002
    title
    Clo/BU4 40mg/m^2
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        21
      3. group Id
        FG002
        num Subjects
        19
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        21
      3. group Id
        FG002
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients with relapsed or refractory hematologic malignancies not in remission received unmanipulated HSCT with CloBu4 conditioning from October 2007 to November 2009 at the University of Michigan. Patients received a clofarabine dose of 20mg/m\^2, 30 mg/m\^2 or 40 mg/m\^2.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice